OncoDaily Newsletter

Subscribe to our newsletter

Subscribe

FDA Approves Giredestrant Plus Everolimus: A New Treatment Option for ESR1-Mutated Advanced Breast Cancer

The Victoria’s Secret Era We Should Be Talking About

Northeast GI Oncology Congress 2026

Zainab Shinkafi-Bagudu։ Working to Accelerate WHO Targets For HPV Vaccination, Screening and Treatment by 2030

AmCORE Study: Treatment Patterns and Survival Across Age Groups in Colorectal Liver Metastases

Sarbajit Mukherjee: New Study Reveals Global and Gender Gaps in Oncology Research Authorship

Rohini Singh Sisodia: The Powerful Difference Between Being Cured and Being Healed

Hana Nimer: Reflections on the GCCA and WPA Congresses in Nairobi – Patient Advocate Events Insights

Immune Oncology

OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.